Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02383810
Recruitment Status : Completed
First Posted : March 9, 2015
Last Update Posted : May 2, 2016
Sponsor:
Collaborator:
Chiltern International Inc.
Information provided by (Responsible Party):
Helsinn Healthcare SA

Brief Summary:

This is a randomized, stratified, double-blind, double-dummy, parallel group, placebo-controlled, dose finding, multicentre, multinational, phase II study in patient with colorectal cancer receiving 5- Fluorouracil (5-FU)-based chemotherapy (FOLFOX or FOLFIRI). Patients will receive, starting from the day of chemotherapy administration, a single daily dose subcutaneously (s.c.) of elsiglutide 10, 20 or 40 mg or placebo for 4 consecutive days. Each patient will be in the study for 3 consecutive chemotherapy cycles. The treatment period for each patient will be 4 consecutive days at each of the first 2 chemotherapy cycles.

The primary objective is to compare the efficacy of 3 s.c. doses of elsiglutide versus (vs.) placebo and vs. each other dose in the prevention of CID in colorectal cancer patients treated with 5-FU based chemotherapy (FOLFOX or FOLFIRI) with no addition of a monoclonal antibody.


Condition or disease Intervention/treatment Phase
Drug and/or Toxin-induced Diarrhea Drug: Elsiglutide Drug: Placebo Phase 2

Detailed Description:

This is a randomized, stratified, double-blind, double-dummy, parallel group, placebo-controlled, dose finding, multicentre, multinational, phase II study in patient with colorectal cancer receiving 5- Fluorouracil (5-FU)-based chemotherapy (FOLFOX -FOLinic acid, Fluorouracil, OXaliplatin chemotherapy regimen - or FOLFIRI - FOLinic acid, Fluorouracil, IRInotecan chemotherapy regimen). Patients will receive, starting from the day of chemotherapy administration, a single daily dose subcutaneously (s.c.) of elsiglutide 10, 20 or 40 mg or placebo for 4 consecutive days. Each patient will be in the study for 3 consecutive chemotherapy cycles. The treatment period for each patient will be 4 consecutive days at each of the first 2 chemotherapy cycles.

Randomization will be performed with a 1:1:1:1 treatment allocation and will be stratified by chemotherapy regimen and country. Two populations are planned for this study.

The population receiving FOLFOX or FOLFIRI without monoclonal antibody is defined as the Target population, while the population concomitantly receiving monoclonal antibody is defined as the Additional population.

Randomization in Target and Additional population are handled independently.

Primary Objective:

To compare the efficacy of 3 s.c. doses of elsiglutide versus (vs.) placebo and vs. each other dose in the prevention of CID in colorectal cancer patients treated with 5-FU based chemotherapy (FOLFOX or FOLFIRI) with no addition of a monoclonal antibody.

Secondary Objectives:

  • As a secondary objective, the efficacy of 3 s.c. doses of elsiglutide vs. placebo and vs. each other dose in the prevention of CID in colorectal cancer patients treated with 5-FU based chemotherapy (FOLFOX or FOLFIRI) given in combination with a monoclonal antibody will be explored.
  • Safety and tolerability of the administered repeated doses of elsiglutide will be evaluated.

Additionally the following secondary objectives will be explored:

  • The pharmacokinetics (PK) of elsiglutide, and its metabolites in each patient who consents to undergo an exposure assessment after the first administration and at steady state. The influence of possible demographic and therapeutic covariates on the PK parameters and their variability will also be investigated. The possible relationship between exposure of elsiglutide and its metabolites and efficacy measures in the target and overall population will be explored.
  • The economic impact of the 3 doses of elsiglutide vs. placebo and each other dose in the treatment of CID.
  • The impact on patient's QoL (quality of life) of the different dosages vs. placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 498 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Different Doses of s.c. Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)
Study Start Date : February 2015
Actual Primary Completion Date : February 2016
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diarrhea

Arm Intervention/treatment
Active Comparator: Elsiglutide 10 mg - target population
Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
Drug: Elsiglutide
Active Comparator: Elsiglutide 20 mg - target population
Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving F-FU based chemotherapy
Drug: Elsiglutide
Active Comparator: Elsiglutide 40 mg - target population
Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
Drug: Elsiglutide
Placebo Comparator: Placebo - target population
Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
Drug: Placebo
Active Comparator: Elsiglutide 10 mg - additional population
Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
Drug: Elsiglutide
Active Comparator: Elsiglutide 20 mg - additional population
Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
Drug: Elsiglutide
Active Comparator: Elsiglutide 40 mg - additional population
Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
Drug: Elsiglutide
Placebo Comparator: Placebo - additional population
Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
Drug: Placebo



Primary Outcome Measures :
  1. Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the first cycle of chemotherapy in the target population [ Time Frame: 15 days ]

Secondary Outcome Measures :
  1. Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the first cycle of chemotherapy in the additional population [ Time Frame: 15 days ]
  2. Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the second and third cycle of chemotherapy - target population [ Time Frame: 15 days of second and third cycle of chemotherapy ]
  3. Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea over the first two cycles of chemotherapy (i.e. in at least one of the first two cycles) - target population [ Time Frame: 15 days of first and second cycle of chemotherapy ]
  4. Proportion of patients experiencing a maximum Grade 1, Grade 2, Grade 3, Grade 4, Grade 5 and any Grade (i.e. ≥ 1) diarrhea by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  5. Proportion of patients experiencing an overall Grade ≥ 2 diarrhea by cycle (Cycle 1, Cycle 2 and Cycle 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  6. Proportion of patients experiencing an overall Grade ≥ 2 diarrhea over the first two cycles of chemotherapy (i.e. in at least one of the first two cycles) - target population [ Time Frame: 15 days of first and second cycle of chemotherapy ]
  7. Time to onset of first event of diarrhea of any Grade (i.e. ≥ 1) and time to onset of first event of diarrhea of Grade ≥ 2 (as assessed by the Investigator) by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  8. Time to first day with diarrhea (as reported by patient in the eDiary) by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  9. Cumulative duration (days) of any Grade (i.e. ≥ 1) diarrhea events and cumulative duration of Grade ≥ 2 diarrhea events (as assessed by the Investigator) by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  10. Cumulative duration (days) of diarrhea events (as assessed by the Investigator) by grade (Grade 1, Grade 2, Grade 3, Grade 4, Grade 5) and by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  11. Number of events of diarrhea by grade (as assessed by the Investigator) by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  12. Number of days with presence of diarrhea (as reported by patient in the eDiary) by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  13. Number of days with presence of at least one bowel movement with stools of consistency 6 or 7 (according to Bristol Stool Form Scale) accompanied by urgency or by fecal incontinence by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  14. Number of days with presence of abdominal discomfort by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  15. Number of days with limitation of self-care activities due to diarrhea by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  16. Proportion of patients: who required i.v. fluids due to CID, who required changes to the primary therapy due to CID, who used rescue medication (i.e. medication used for treatment of diarrhea) by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  17. Proportion of patients having a maximum Grade ≥ 2 diarrhea - shift from Cycle 1 to Cycle 2 and from Cycle 2 to Cycle 3 - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  18. Proportion of patients having a maximum Grade ≥ 1 diarrhea - shift from Cycle 1 to Cycle 2 and from Cycle 2 to Cycle 3 - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  19. Proportion of patients having an overall Grade ≥ 2 diarrhea - shift from Cycle 1 to Cycle 2 and from Cycle 2 to Cycle 3 - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  20. Proportion of patients having an overall Grade ≥ 1 diarrhea - shift from Cycle 1 to Cycle 2 and from Cycle 2 to Cycle 3 - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]
  21. Time trend of the citrulline plasma concentrations in Cycles 1, 2 and 3 - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent
  2. Male or female > 18 years of age;
  3. Histologically or cytologically confirmed diagnosis of colorectal cancer

    • Inclusion in the Target Population: Scheduled to receive at least 3 consecutive cycles of the same regimen of FOLFOX or FOLFIRI without monoclonal antibody;
    • Inclusion in the Additional Population: Scheduled to receive at least 3 consecutive cycles of the same regimen of FOLFOX or FOLFIRI in combination with monoclonal antibody;
  4. A performance status of ≤ 2 according to the Eastern Cooperative Oncology Group (ECOG) scale;
  5. Non-childbearing female patient or female patient of childbearing potential using reliable contraceptive measures and having negative pregnancy test before treatment administration;
  6. Able to read, understand, follow the study procedure and complete patient diary.

Inclusion criteria will be checked during the screening visit. Inclusion criteria 4 and 6 will be re-checked as applicable on Day 1 of Cycle 1 and Cycle 2.

Exclusion Criteria:

  1. Any investigational drugs within 30 days before enrollment or foreseen use of investigational agents during the study;
  2. Treatment with chemotherapy of any type within 12 months before enrollment;
  3. Patient with any type of ostomy (temporary ostomy should be closed at least 6 months prior to enrollment);
  4. Patient who underwent total colectomy;
  5. Patient who had abdominal-perineal resection or surgery leaving the patient without a functioning rectum;
  6. Any radiotherapy to the abdomen or pelvis in the 6 months prior to enrollment;
  7. Scheduled to receive radiotherapy to abdomen or pelvis during the study;
  8. a) Exclusion from the Target population Scheduled to receive any concomitant chemotherapeutic agent, other than FOLFOX or FOLFIRI agents; any type of monoclonal antibodies;

8. b) Exclusion from the Additional population Scheduled to receive any concomitant chemotherapeutic agent, other than FOLFOX or FOLFIRI agents;

9. Any type of condition leading to diarrhea, including but not limited to inflammatory bowel diseases (e.g. ulcerative colitis and Crohn's disease), diarrhea of presumed or confirmed infectious origin and irritable bowel syndrome, celiac disease, lactose intolerance, pancreas, liver or diverticular disease, alcohol abuse;

10. History of chronic (≥ 30 consecutive days) use of laxatives;

11. Active and ongoing systemic infection;

12. Lactating woman;

13. History of hypersensitivity or allergies to drugs or compounds potentially related to this investigational drug class;

14. Previous exposure to Glucagon-like peptide-2 (GLP-2) or other compounds in this investigational drug class;

15. Patient who participated in a previous study with elsiglutide;

16. Patient with abnormalities in selected laboratory parameters, including:

  • Aspartate aminotransferase (AST) ≥ 5 x upper limit of normal
  • Alanine aminotransferase (ALT) ≥ 5 x upper limit of normal
  • Bilirubin > 1.5 x upper limit of normal
  • Creatinine > 2 mg/dL (177 μmol/L)
  • Albumine < 2 g/dL (20 g/L)
  • Neutrophils < 1.5 x109/L
  • Platelet count < 100 x109/L ;

    17. Any illness or condition that, in the opinion of the investigator, may confound the results of the study or pose unwarranted risk in administering the investigational product to the patient;

    18. Any medical condition that precludes the administration of chemotherapy;

    19. Use of laxatives within 7 days prior to study Day 1;

    20. Use of antibiotics within 7 days prior to study Day 1;

    21. Any diarrhea in the 48 hours preceding study drug administration on Day 1;

    22. Major surgery within the previous 21 days before study Day 1;

    23. Use of anti-diarrheal agents and probiotics within the 48 hours prior to study drug administration on study Day 1.

Exclusion criteria 1 to 18 will be checked during the screening visit. Exclusion criteria 19 to 23 should be checked on Day 1 of Cycle 1. Exclusion criteria 7, 8, 9, 11 and 17 to 23 will be re-checked on Day 1 of Cycle 2.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02383810


Locations
Show Show 54 study locations
Sponsors and Collaborators
Helsinn Healthcare SA
Chiltern International Inc.

Layout table for additonal information
Responsible Party: Helsinn Healthcare SA
ClinicalTrials.gov Identifier: NCT02383810    
Other Study ID Numbers: TIDE-13-22
First Posted: March 9, 2015    Key Record Dates
Last Update Posted: May 2, 2016
Last Verified: April 2016
Keywords provided by Helsinn Healthcare SA:
Chemotherapy Induced Diarrhea (CID)
Additional relevant MeSH terms:
Layout table for MeSH terms
Diarrhea
Signs and Symptoms, Digestive
Signs and Symptoms